One of the challenges that life science companies are faced with as they search for a financial group to work with is their cash burn. Even late stage biotech companies rely heavily on equity received through investment firms and other sources to cover their losses. These losses are a normal part of new pharmaceutical research & development. Medical devices, on the other hand, are subject to shorter and less expensive FDA approval processes. This means that these businesses often support their own debt without the need for help from a venture capital firm.